ThirtyFiveBio, an Oxford, UK-based biotechnology company developing small molecule inhibitors for the treatment of gastrointestinal (GI) disease, closed a Bridge financing of an undisclosed amount.
The round included participation from AbbVie Ventures, Canaan and new investor Mayewell Capital.
The company intends to use the funds to support the continued development of the its GPR35 inhibitor program, which is currently advancing through preclinical development, including investigational new drug (IND)-enabling studies.
ThirtyFiveBio is a biotechnology company developing small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease. It has built scientific thought leadership in the biology of GPR35 and the role that it plays in GI disease, including digestive tract colitis and cancers. The company has leveraged its enabled drug discovery platform to identify multiple families of small-molecule GPR35 inhibitors with priority molecules in development candidate nomination studies.
Created by Molecule to Medicine (MTM), a drug discovery and development ecosystem, and Canaan Partners, the company has raised nearly $25M in financing to date.
FinSMEs
15/04/2025